Last reviewed · How we verify

NCT04119557

A Study of LY3471851 in Participants With Psoriasis

Completed Phase 1 Last updated 20 February 2024
What this trial tests

Phase 1 trial testing Placebo in Psoriasis in 30 participants. Completed in 21 July 2021.

Timeline
26 November 2019
Primary endpoint
21 July 2021
21 July 2021

Quick facts

Lead sponsorNektar Therapeutics
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposebasic science
Enrollment30
Start date26 November 2019
Primary completion21 July 2021
Estimated completion21 July 2021
Sites24 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Nektar Therapeutics — full company profile →

Who can join

Adults 18 to 70, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to learn more about the safety of LY3471851 when given by injection just under the skin to participants with psoriasis. The study will last up to 48 weeks and may include up to 23 visits to the study center.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.
    Raeber ME, Sahin D, Karakus U, Boyman O. · · 2023 · cited 139× · PMID 37004361 · DOI 10.1016/j.ebiom.2023.104539
  2. IL-2-based approaches to Treg enhancement.
    Harris F, Berdugo YA, Tree T. · · 2023 · cited 81× · PMID 36399073 · DOI 10.1093/cei/uxac105
  3. Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.
    Moorman CD, Sohn SJ, Phee H. · · 2021 · cited 77× · PMID 33854514 · DOI 10.3389/fimmu.2021.657768
  4. "IL-2 immunotherapy for targeting regulatory T cells in autoimmunity".
    Lykhopiy V, Malviya V, Humblet-Baron S, Schlenner SM. · · 2023 · cited 61× · PMID 37741949 · DOI 10.1038/s41435-023-00221-y
  5. NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases.
    Dixit N, Fanton C, Langowski JL, Kirksey Y, et al · · 2021 · cited 45× · PMID 34041473 · DOI 10.1016/j.jtauto.2021.100103
  6. Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis.
    Tseng JC, Chang YC, Huang CM, Hsu LC, et al · · 2021 · cited 27× · PMID 34371756 · DOI 10.3390/pharmaceutics13071064
  7. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.
    Silverberg JI, Rosmarin D, Chovatiya R, Bieber T, et al · · 2024 · cited 19× · PMID 39455575 · DOI 10.1038/s41467-024-53384-1
  8. Tissue-specific roles of regulatory T cells: mechanisms of suppression and beyond along with emerging therapeutic insights in autoimmune indications.
    Jugder BE, Park E, Du L, Jawale C, et al · · 2025 · cited 3× · PMID 40933988 · DOI 10.3389/fimmu.2025.1650451

Verify or expand the search:

Other trials of LY3471851

Trials testing the same drug.

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

Other Nektar Therapeutics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04119557.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing